0.16Open0.16Pre Close0 Volume15 Open Interest1.00Strike Price0.00Turnover206.64%IV20.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type-0.3586Delta0.7572Gamma6.63Leverage Ratio-0.0050Theta-0.0003Rho-2.38Eff Leverage0.0009Vega
CytomX Stock Discussion
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
No comment yet